Close Menu

This article has been updated from a previous version to include DermTech's share price in Friday afternoon trading on the Nasdaq.

NEW YORK ─ Skin cancer diagnostic company DermTech this week announced that it has inked a contract that makes its Pigmented Lesion Assay available to approximately 6 million Blue Cross Blue Shield of Texas (BCBSTX) members.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.